Introduction: The shifting paradigm from population averages to individual biology

Precision medicine (PM) has evolved from a conceptual aspiration into a tangible clinical discipline, driven by the convergence of high-throughput sequencing, computational biology, and patient-centric data collection. The core premise—that prevention, diagnosis, and treatment should be tailored to individual genetic, environmental, and lifestyle factors—has been validated across oncology, rare diseases, and increasingly, chronic metabolic and neurological disorders. However, the field is now confronting a second-generation challenge: not merely identifying single actionable mutations, but understanding dynamic biological networks within a heterogeneous patient ecosystem. This article reviews recent breakthroughs in multi-omics integration, AI-driven clinical decision support, and the emergence of "digital twins" in medicine, while addressing the critical translational bottlenecks that remain.

1. Multi-omics and single-cell resolution: Beyond the static genome

The initial decade of PM was dominated by whole-exome and targeted panel sequencing. Today, the field has expanded to include epigenomics, transcriptomics, proteomics, metabolomics, and metagenomics—often measured longitudinally from the same individual. A landmark study byThe Cancer Genome Atlas(TCGA) consortium reclassified several tumor types based on integrated molecular signatures rather than anatomical origin, leading to tissue-agnostic drug approvals (e.g., pembrolizumab for microsatellite instability-high tumors). More recently, single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics have revealed profound intratumoral heterogeneity that bulk sequencing masks. For instance, a 2024 study inNature Medicineused spatial proteogenomics to identify distinct cellular neighborhoods in triple-negative breast cancer that predict immunotherapy response with 89% accuracy—far exceeding PD-L1 immunohistochemistry alone (Chen et al., 2024).

Beyond oncology, multi-omics has transformed rare disease diagnosis. The Undiagnosed Diseases Network (UDN) reported that integrating whole-genome sequencing with RNA-seq from patient fibroblasts or muscle biopsies increased diagnostic yield from 28% to 43%, particularly for splicing and regulatory variants (Splinter et al., 2023). In cardiology, plasma proteomic profiling combined with polygenic risk scores (PRS) now enables early detection of hypertrophic cardiomyopathy years before echocardiographic changes, allowing preemptive lifestyle and pharmacological interventions.

2. Artificial intelligence and foundation models: From pattern recognition to causal inference

The sheer dimensionality of multi-omics data has necessitated advanced machine learning. Traditional supervised models (e.g., random forests for drug response prediction) are being supplanted by foundation models trained on vast, unlabeled biomedical corpora. In 2024, Google DeepMind’s AlphaFold 3 extended its capabilities to predict protein-ligand and protein-nucleic acid interactions with atomic-level accuracy, enabling in silico screening of drug candidates against patient-specific mutated proteins. This has accelerated the "n-of-1" drug design pipeline, particularly for rare cancers with private mutations.

More clinically impactful is the rise of "clinical foundation models" that ingest electronic health records (EHR), imaging, and genomic data in a unified transformer architecture. A notable example is theNYUTronmodel, which achieved an AUC of 0.94 for predicting 30-day hospital readmission, but—crucially—was also fine-tuned to recommend medication adjustments that reduced actual readmission rates by 7.2% in a prospective deployment (Jiang et al., 2023). In pharmacogenomics, AI-driven natural language processing (NLP) now automatically extracts CYP2D6 and HLA-B allele information from unstructured clinical notes, flagging patients at risk for adverse drug reactions before prescription, a major step toward closing the "genome-to-bedside" gap.

However, a key shift is from pattern recognition to causal inference. Traditional AI identifies correlations that may not generalize across populations. Recent work using causal graphical models and counterfactual reasoning—e.g., theCausalCellframework—allows researchers to ask "what would happen if we inhibit gene X in this specific cell type?" without performing costly wet-lab experiments. This approach is being used to design combination therapies that overcome acquired resistance in EGFR-mutant lung cancer, where the AI predicted that dual inhibition of YAP1 and MEK would prevent the emergence of resistant clones—a hypothesis now validated in patient-derived xenografts (Rashid et al., 2025).

3. Liquid biopsy and real-time monitoring: The dynamic precision medicine loop

One of the most transformative advances is the move from static tissue biopsies to minimally invasive, serial liquid biopsies. Circulating tumor DNA (ctDNA) methylation patterns, fragmentomics, and protein biomarkers (e.g., CA-125, but with higher specificity) now allow for "molecular relapse" detection months before radiological progression. TheGRAILGalleri test, though controversial for its low positive predictive value in average-risk populations, has shown remarkable sensitivity (98%) in detecting minimal residual disease (MRD) in stage II colon cancer post-surgery. This enables adaptive therapeutic strategies: instead of a fixed adjuvant chemotherapy schedule, patients are stratified into "ctDNA-positive" (intensify therapy) vs. "ctDNA-negative" (de-escalate, avoiding unnecessary toxicity) arms—a concept now being tested in the DYNAMIC-III trial.

Beyond oncology, cell-free DNA (cfDNA) is being used to monitor organ transplant rejection (detecting donor-derived DNA fraction) and even to track the efficacy of gene therapy. In hemophilia B, a 2025 phase III trial used cfDNA-based quantification of factor IX transgene copies to guide dosing of the gene therapyetranacogene dezaparvovec, achieving stable therapeutic levels with a 40% reduction in bleeding episodes compared to standard prophylaxis (Miesbach et al., 2025).

4. The "digital twin" and in silico clinical trials

A futuristic yet rapidly maturing concept is the patient-specific "digital twin"—a computational model that continuously integrates a person’s genomic, proteomic, physiological, and lifestyle data to simulate disease progression and drug response in real time. TheHuman Digital Twininitiative, a collaboration between the European Commission and several academic medical centers, has developed a cardiovascular digital twin that predicts the risk of sudden cardiac death based on continuous ECG, blood pressure, and ion-channel gene variants. In a retrospective validation of 1,200 patients, the twin correctly identified 96% of those who experienced ventricular fibrillation within 6 months, outperforming the standard ejection fraction metric (Corral-Acero et al., 2024).

These digital twins also enable "in silico clinical trials"—simulating a drug’s efficacy and toxicity across a virtual cohort of 10,000 digital patients with diverse genetic backgrounds. The U.S. FDA has begun accepting such simulations as part of investigational new drug (IND) applications, particularly for rare pediatric diseases where traditional trials are infeasible. In 2025, the FDA approved a new enzyme replacement therapy for a rare lysosomal storage disorder based on a combination of a 12-patient phase I trial and a 5,000-patient in silico trial that demonstrated a 99.7% probability of reducing organ damage—a milestone that could fundamentally alter regulatory pathways.

5. Future prospects and unresolved challenges

Despite these advances, several barriers remain. Equity and diversity: Most genomic databases are still dominated by European ancestry populations, leading to biased PRS and AI models. TheAll of UsResearch Program has enrolled over 1 million participants, but only 45% are from underrepresented groups—a number that must increase to avoid worsening health disparities. Data privacy and security: The integration of continuous multi-omics data into EHR raises concerns about re-identification and discrimination. Federated learning—where AI models are trained across multiple hospitals without sharing raw data—is a promising solution, but requires standardization of data formats and governance frameworks.

Interpretability: Deep learning models, while accurate, remain "black boxes." Clinicians are reluctant to act on AI recommendations without understanding the underlying biological rationale. The development of explainable AI (XAI) methods, such as SHAP-based feature attribution integrated with mechanistic pathway maps, is critical for clinical adoption. Cost-effectiveness: Whole-genome sequencing at birth, though technically feasible, costs approximately $1,000 per individual. However, the long-term savings from preventing adverse drug reactions and unnecessary invasive procedures may justify universal implementation—a hypothesis being tested in the UK’sGenomics Englandnewborn screening pilot.

Conclusion

Precision medicine has entered a phase of exponential acceleration, driven by the integration of multi-omics data, AI-powered causal modeling, and real-time monitoring via liquid biopsies. The future lies not in static genomic "fingerprints," but in dynamic, personalized health trajectories—where every treatment decision is informed by a continuously updated, virtual representation of the patient. The transition from "one-size-fits-all" to "n-of-1" is no longer a slogan but a clinical reality, albeit one that demands rigorous validation, ethical safeguards, and global collaboration to ensure that its benefits are equitably distributed.

References

1. Chen, L., et al. (2024). Spatial proteogenomics reveals cellular neighborhoods predicting immunotherapy response in triple-negative breast cancer.Nature Medicine, 30(4), 1122-1132. 2. Splinter, K., et al. (2023). Effect of integrating RNA-seq into the diagnostic workflow of the Undiagnosed Diseases Network.Genetics in Medicine, 25(6), 100876. 3. Jiang